<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002984" GROUP_ID="AIRWAYS" ID="133399072816010919" MERGED_FROM="" MODIFIED="2008-07-30 16:58:31 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): Beta-2 agonists for acute exacerbations of COPD&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-07-30 15:57:03 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" REVIEW_NO="ISAB-COP" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-07-30 16:58:31 +0200" MODIFIED_BY="Toby Lasserson">
<TITLE>Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease</TITLE>
<CONTACT MODIFIED="2008-07-30 16:58:31 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="12392" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cynthia</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Brown</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>cdbrownmd@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Section of Pulmonary &amp; Critical Care Medicine</DEPARTMENT><ORGANISATION>Brody School of Medicine</ORGANISATION><ADDRESS_1>Room E-149B, Brody Medical Science Building</ADDRESS_1><ADDRESS_2>600 Moye Blvd</ADDRESS_2><CITY>Greenville</CITY><ZIP>27858</ZIP><REGION>North Carolina</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>252-744-2007</PHONE_1><PHONE_2>252-744-4653</PHONE_2><FAX_1>252-744-4887</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-07-30 16:58:31 +0200" MODIFIED_BY="Toby Lasserson"><PERSON ID="12392" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cynthia</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Brown</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>cdbrownmd@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Section of Pulmonary &amp; Critical Care Medicine</DEPARTMENT><ORGANISATION>Brody School of Medicine</ORGANISATION><ADDRESS_1>Room E-149B, Brody Medical Science Building</ADDRESS_1><ADDRESS_2>600 Moye Blvd</ADDRESS_2><CITY>Greenville</CITY><ZIP>27858</ZIP><REGION>North Carolina</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>252-744-2007</PHONE_1><PHONE_2>252-744-4653</PHONE_2><FAX_1>252-744-4887</FAX_1></ADDRESS></PERSON><PERSON ID="6867" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Douglas</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>McCrory</LAST_NAME><SUFFIX>MD, MHS</SUFFIX><POSITION>Associate Professor of Medicine</POSITION><EMAIL_1>mccro002@mc.duke.edu</EMAIL_1><URL>www.clinpol.mc.duke.edu</URL><ADDRESS><DEPARTMENT>Center for Clinical Health Policy Research</DEPARTMENT><ORGANISATION>Duke University</ORGANISATION><ADDRESS_1>2200 W. Main Street, Suite 220</ADDRESS_1><CITY>Durham</CITY><ZIP>27705</ZIP><REGION>NC</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 919 286 9225</PHONE_1><PHONE_2>+1 919 286 3399</PHONE_2><FAX_1>+1 919 286 5601</FAX_1></ADDRESS></PERSON><PERSON ID="8293" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>John</FIRST_NAME><LAST_NAME>White</LAST_NAME><POSITION>Consultant Physician</POSITION><EMAIL_1>john.white@york.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Respiratory Medicine</DEPARTMENT><ORGANISATION>York District Hospital</ORGANISATION><ADDRESS_1>Wigginton Rd</ADDRESS_1><CITY>York</CITY><ZIP>YO31 8HE</ZIP><REGION>North Yorks</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01904 453481</PHONE_1><PHONE_2>01904 631313 ext: 3481</PHONE_2><FAX_1>01904 454747</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-30 16:58:31 +0200" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Minor update: 08/05/02&lt;/p&gt;&lt;p&gt;New studies sought but none found: 01/02/02&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 08/05/02&lt;/p&gt;">
<UP_TO_DATE>
<DATE DAY="8" MONTH="5" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="5" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2003"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2001"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="30" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="5" MONTH="10" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Agency for Health Care Policy and Research (Contract No. 290-97-0014)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Agency for Healthcare Research &amp; Quality - National Research Service Award</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Durham Veterans Affairs Hospital</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-07-30 15:57:03 +0100" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-07-30 15:52:42 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-30 15:52:42 +0100" MODIFIED_BY="Toby J Lasserson">Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease</TITLE>
<SUMMARY_BODY>
<P>During an acute worsening of chronic obstructive pulmonary disease, there may be a worsening in airway function. Two different types of drugs may be given as inhaled therapy to improve this: anticholinergic drugs such as ipratropium and beta2-agonists. These days the drugs of the latter type that are used for acute COPD are salbutamol and terbutaline, but neither of these drugs have been used in the only studies that we could find. We found only three small studies. Overall, both types of drug showed a small but worthwhile effect. There was no difference between them. Our review was not designed to test whether they would have had a greater effect if both were given at the same time.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-30 15:52:32 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>Inhaled short acting beta2 adrenergic agonists and ipratropium bromide are both used in the treatment of acute exacerbations of chronic obstructive pulmonary disease.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>In patients with acute exacerbations of COPD to: 1. To assess the efficacy of short-acting beta-2 agonists against placebo ; 2. Compare the efficacy of short-acting beta-2 agonists and ipratropium.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>A comprehensive search of the literature was carried out of EMBASE, MEDLINE, CINAHL and the Cochrane COPD trials register was carried out using the terms: bronchodilator* OR albuterol OR metaproterenol OR terbutaline OR isoetharine OR pirbuterol OR salbutamol OR beta-2 agonist.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All trials that appeared to be relevant were assessed by two reviewers who independently selected trials for inclusion. Differences were resolved by consensus. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>All trials that appeared to be relevant were assessed by two reviewers who independently selected trials for inclusion. Differences were resolved by consensus. References listed in each included trial were searched for additional trial reports. Trials were combined using Review Manager using a fixed effects model. The size of the treatment effects were tested for heterogeneity. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-07-30 15:52:32 +0100" MODIFIED_BY="Toby J Lasserson">
<P>We identified no placebo-controlled comparisons of beta-2 agonists. Three studies permitted comparison of ipratropium to an inhaled beta-2 agonist. These studies included a total of 103 patients. The beta2-agonists used were: fenoterol and metaproterenol. One study was a parallel group trial of regular therapy for seven days. The other two were cross over studies of single dose treatments, with efficacy measured 90 min post dose. There was no washout period between treatments.</P>
<P>Both treatments produced an improvement in forced expiratory volume (FEV1) after 90 min in the range 150-250 ml. The was no difference between treatments, mean difference in FEV1 10 ml; 95% CI -220, 230 ml. In one small crossover study (n=10) there was a significant improvement in arterial PaO2 after 30 minutes with ipratropium (+5.8 mm Hg ± 3.0 (SEM)) compared to metaproterenol (-6.2 ± 1.2 mm Hg), but this was not significant at 90 min. There were no data concerning respiratory symptoms. The crossover studies showed no evidence of an additive effect of the two treatments, although they were not designed specifically to test this. An update search conducted in February 2002 yielded one further excluded study.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There are few controlled trial data concerning the use of inhaled beta2-agonist agents in acute exacerbations of COPD and none that have compared these agents directly with placebo. None of the studies used the more modern beta2-agonists used most widely in this setting (salbutamol and terbutaline). Beta2-agonists and ipratropium both produce small improvements in FEV1, but beta2-agonists may worsen PaO2 for a period. We could not draw conclusions concerning possible additive effects. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-07-30 15:57:03 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND>
<P>The natural history of moderate to severe COPD is punctuated by acute exacerbations in which worsening symptoms of dyspnea and an increase in amount or purulence of sputum may be accompanied by chest discomfort, fever and other constitutional symptoms. Acute exacerbations are often the reason that those with mild disease seek medical care. Treatment is often multifaceted with antibiotics, corticosteroids and bronchodilators.</P>
<P>Part of the dyspnoea during acute exacerbations is due to broncho-constriction. To some extent the severity of the exacerbation is based on the degree of constriction/obstruction present. Along with airway inflammation, contraction of smooth muscle within the bronchial tree is responsible for this phenomenon. Short acting bronchodilators such as beta-2 agonists, ipratropium bromide (an anticholinergic agent) and methylxanthines reduce airway smooth muscle constriction. These drugs may also have an effect on secretions, mucus production ciliary function. </P>
<P>Short acting beta2-agonists and ipratropium are widely used in the management of acute exacerbations of COPD. This review was originally designed to assess the benefit of short-acting beta2-agonists alone vs placebo, but no trials of this kind were found, all compared a beta2-agonist with ipratropium. For this reason the objective of the review was changed to compare these two classes of agent.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the effects of inhaled short-acting beta-2 agonists and ipratropium on lung function and dyspnoea in patients with an acute exacerbation of COPD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-30 15:53:24 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomized controlled trials comparing inhaled short-acting beta-2 agonists with ipratropium. Results from patients with acute asthma were excluded. Studies of acute exacerbations in any setting were permitted, although we expected that most studies would be performed in the emergency room or within hospital.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies were included if the participants were adult patients with a known diagnosis of COPD and symptoms of an acute exacerbation, defined as increased shortness of breath, increased sputum production, or sputum purulence (the 'Winnipeg criteria' for defining/diagnosing acute exacerbations of COPD (<LINK REF="REF-Anthonisen-1987" TYPE="REFERENCE">Anthonisen 1987</LINK>, <LINK REF="REF-Murphy-1992" TYPE="REFERENCE">Murphy 1992</LINK>)).</P>
<P>Studies of patients receiving ventilatory assistance were excluded. While we assumed that most cases of exacerbation are due to infection we did not limit the target population to those patients for whom infection was the suspected etiology. We expect that patients with acute exacerbations of COPD may have various comorbidities (such as congestive heart failure or pulmonary embolus) or complications of COPD (e.g. pneumothorax) as the etiology of exacerbation of their symptoms. We required that studies in some way assured that patients with other reasons for these symptoms were not studied.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any studies employing short acting beta2-agonists administered by inhalation via nebulizer or metered dose inhaler. Relevant agents include salbutamol (albuterol), metaproterenol, terbutaline, isoetharine, and pirbuterol.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Outcome measures include:<BR/>1. Lung function measurements, forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) or peak expiratory flow rate (PEFR)<BR/>2. Arterial blood gas measurements<BR/>3. Symptom scores<BR/>The above short term outcomes will be assessed as post-treatment data or change from pre- to post-treatment in two time frames - within 90 minutes and greater than 1 day.</P>
<P>Outcomes also to be assessed:<BR/>4. Health status or quality of life assessments<BR/>5. Functional capacity - timed walking tests, endurance tests<BR/>6. Health services utilization measures, duration of hospitalization or time to emergency room discharge<BR/>7. Hospital readmission or return to emergency room<BR/>8. Mortality<BR/>9. Adverse drug reactions.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-30 15:53:00 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The Cochrane Airways Group has developed a COPD-RCT register through a comprehensive search of EMBASE, MEDLINE, and CINAHL. An initial search of the register was carried out using the search terms: bronchodilator* OR albuterol OR metaproterenol OR terbutaline OR isoetharine OR pirbuterol OR salbutamol. Concurrently, similar searches of MEDLINE and EMBASE were performed.</P>
<P>References listed in each included trial were searched for additional trial reports.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-30 15:53:24 +0100" MODIFIED_BY="Toby J Lasserson">
<P>All trials that appeared to be relevant were assessed by two reviewers who independently selected trials for inclusion. Differences were resolved by consensus.</P>
<P>All trials were entered and scored using the following principles:<BR/>Grade A - Double blind<BR/>Grade B - Single blind<BR/>Grade C - Obviously not blinded or not known</P>
<P>The internal validity of individual trials was assessed using the scale devised by Jadad (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>), which will be operationalized as follows:</P>
<P>(1) Was the study described as randomized? (1=yes; 0=no)<BR/>(2) Was the method of randomization well described and adequate? (0=not described; 1=described and adequate; -1=described, but not adequate)<BR/>(3) Was the study described as double-blind? (1=yes; 0=no)<BR/>(4) Was the method of double-blinding well described and adequate? (0=not described; 1=described and adequate; -1=described, but not adequate)<BR/>(5) Was there a description of withdrawals and dropouts sufficient to determine the number of patients in each treatment group entering and completing the trial? (1=yes; 0=no).</P>
<P>The external validity of the trials was described using the following features:<BR/>(1) Validity of the underlying COPD diagnosis:<BR/>(a) Is COPD diagnosis based on spirometry-based criteria (e.g. ATS (<LINK REF="REF-American-1995" TYPE="REFERENCE">American 1995</LINK>) or Siafakas (<LINK REF="REF-Siafakas-1995" TYPE="REFERENCE">Siafakas 1995</LINK>))?<BR/>(b) Is the baseline stable FEV1 of study population described?<BR/>(2) Validity of diagnosis of AECB (Acute exacerbation of chronic bronchitis):<BR/>Does the definition of AECB include at least two of the following: increased sputum production, increased sputum volume, and increased dyspnea?<BR/>(3) Characterization of severity of AECB:<BR/>Does the study describe the severity of AECB at enrolment based upon at least two of the following domains:<BR/>(a) Mental status change<BR/>(b) Work of breathing (e.g. respiratory rate or use of accessory muscles)?<BR/>(c) Ventilatory status (e.g. FEV1 or PEFR, O2 saturation or PaO2 and PaCO2)?<BR/>(4) Duration of follow-up:<BR/>Is there an outcome assessment at 24 hours or longer?</P>
<SUBSECTION>
<HEADING LEVEL="6">Statistical considerations</HEADING>
<P>Trials were combined using Review Manager 4.0.4 using a fixed effects model The size of the treatment effects were tested for heterogeneity. If significant heterogeneity were found, an attempt would be made to explain the differences based on the clinical characteristics of the included studies. Clinically dissimilar studies would not be combined. However, when a group of studies with heterogeneous results appeared clinically similar the study estimates were combined using a random effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Planned subgroup analyses included:</HEADING>
<P>1. A comparison of studies using concurrent medication vs those that did not. Such co-interventions may include other bronchodilating agents, mucus clearing therapies or corticosteroids.<BR/>2. A comparison of studies by severity of exacerbation of included patients or degree of airways obstruction.<BR/>3. A comparison of studies utilizing delivery of bronchodilators by metered dose inhaler versus nebulizer.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-30 15:57:03 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-07-30 15:55:08 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-07-30 15:54:22 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A combined database of 1343 entries was created from the results of MEDLINE and COPD-RCT register literature searches. After excluding articles that focused on pediatric patients and/or asthma there were 430 entries for further evaluation. We then excluded papers where stable COPD patients were the study population. Twenty five papers were selected for full-text evaluation for inclusion in the review. Of those 25 papers only three were RCTs that met the criteria for inclusion. (Note: we identified no randomised placebo-controlled comparisons of beta-2 agonists). Of the three studies one was a parallel group study of regular nebulised fenoterol vs ipratropium over 7 days (<LINK REF="STD-Backman-1985" TYPE="STUDY">Backman 1985</LINK>). The other two were single dose cross-over studies with assessments at 90 mins, one using metaproterenol or ipratropium via a metered dose inhalers (<LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK>), the other using nebulised fenoterol or ipratropium (<LINK REF="STD-Rebuck-1987" TYPE="STUDY">Rebuck 1987</LINK>). An update search conducted in February 2002 yielded one further excluded study (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-07-30 15:55:08 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Three studies met the eligibility criteria of this review. </P>
<P>All of the studies were small, with a total of 103 patients included. </P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All three studies included in this review were randomized, controlled, double-blind trials. <LINK REF="STD-Rebuck-1987" TYPE="STUDY">Rebuck 1987</LINK> used a computer-generated randomization schedule, but <LINK REF="STD-Backman-1985" TYPE="STUDY">Backman 1985</LINK> and <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK> did not explain the methods used to randomise patients.</P>
<P>Two studies (<LINK REF="STD-Rebuck-1987" TYPE="STUDY">Rebuck 1987</LINK>, <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK>) used the ATS diagnostic criteria for COPD (<LINK REF="REF-American-1995" TYPE="REFERENCE">American 1995</LINK>). <LINK REF="STD-Backman-1985" TYPE="STUDY">Backman 1985</LINK> used the British MRC criteria. Only <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK> provided the criteria used to diagnose exacerbations. Severity of disease was assessed using FEV1 and/or PEFR at the time of entry into the study. Spirometry was also the used to evaluate the outcomes of treatment. </P>
<P>The following parameters were used to measure efficacy: change in FEV1, PEFR, PaO2, and PaCO2. Because all the patients were admitted to hospitals for care of severe exacerbations the patient population tended to include those patients with more severe disease (i.e. FEV1&lt;1 litre). There was also a lack of standardization of co-interventions in the studies. All allowed the use of additional medications, such as corticosteroids, theophylline, and antibiotics; however, use of these interventions was left to the discretion of the admitting physician.</P>
<P>Most studies did not report precisely the statistical information we required - namely the variance of the change in outcomes from pre- to post-treatment. We had to estimate the variance of the changes based on the sum of the pre-and post-treatment variances. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-30 15:57:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>There were small mean improvements in FEV1 over the first 90 minutes of treatment with both beta2-agonists and ipratropium. These were in the range 150-250 ml. There was no difference in the size of the response between the two treatments, mean difference: 10 ml; 95% CI -220 to 230 ml (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). There were limited data available for short-term differences in change in PEFR and long-term differences in change in FEV1 and PEFR.</P>
<P>Data on changes in blood gases were limited. Only two of the three studies (<LINK REF="STD-Backman-1985" TYPE="STUDY">Backman 1985</LINK>, <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK>) reported such changes. Neither found any differences in short- or long-term PaO2 between treatments, but only one (<LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK>) provided actual data for interpretation. They found an increase of PaO2, in those subjects using ipratropium bromide and a decrease in those using metaproterenol at 60 minutes, that was statistically significant. However, levels had returned to baseline for both study groups at 90 minutes.</P>
<P>Symptom or dyspnoea scores were not reported and there were no data on length of hospital stay.</P>
<P>Adverse drug reactions were reported by a minority of subjects in all 3 studies. <LINK REF="STD-Backman-1985" TYPE="STUDY">Backman 1985</LINK> had one person in each group describe an unexplained "strange feeling" after using ipratropium bromide or fenoterol. Dry mouth and tremor were the most commonly reported reactions by <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK> and <LINK REF="STD-Rebuck-1987" TYPE="STUDY">Rebuck 1987</LINK>. One subject in each group experienced dry mouth in the study conducted by <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK>; <LINK REF="STD-Rebuck-1987" TYPE="STUDY">Rebuck 1987</LINK> reports 4 patients in the beta-2 agonist group, and 1 in the ipratropium bromide group for the same reaction. Tremor occurred in similar numbers with 2 in each of the groups of <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK> and 3 each for those reported by <LINK REF="STD-Rebuck-1987" TYPE="STUDY">Rebuck 1987</LINK>.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Few studies of inhaled beta-2 agonists have been performed in populations with acute exacerbations of COPD. The studies available describe the short- and intermediate-term impact on spirometric function. The studies show that there is no difference in efficacy between beta-2 agonists and ipratropium bromide. All of these studies were small, and none were powered to test equivalence rather than superiority (more participants are required for equivalence studies). In addition since we had to estimate the variance of the changes based on the sum of the pre-and post-treatment variances, this may have inflated the size of the estimated variance for the change in measurement used in the analysis and decreased the power of the analysis to detect a difference. Despite all of these considerations, it unlikely that there is a difference in the relatively efficacy of these two treatments that is clinically worthwhile. In all outcomes, the differences between treatments was very close to zero, with wide confidence intervals around these estimates. </P>
<P>It should be noted that all drug doses were at or above what is considered standard and acceptable practice. The trials identified for inclusion in this review were not designed to test for an additive effect between ipratropium and beta2-agonists. Overall, patients appeared to have achieved maximal bronchodilation with the first drug given, since no further broncho-dilatation was seen with the second agent, as exemplified by <LINK REF="STD-Karpel-1990" TYPE="STUDY">Karpel 1990</LINK>. However one of these studies did find that in patients with acute asthma, a combination of ipratropium and fenoterol did produce a greater effect than either drug alone.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>In acute exacerbations of COPD, short-acting beta-2 agonists and ipratropium appear to produce short-term improvements of FEV1 and PEFR of very similar magnitude. The average improvement in FEV1 in response to a single dose of either drug lay in the range 150-250 ml. The trials included in the review provide no evidence for a synergistic effect between these two agents, although they were not designed to address this issue directly.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Few studies of bronchodilating drugs have been performed in populations with acute exacerbation of COPD. Most studies included one or more additional medications, usually a corticosteroid, an antibiotic, or both, which may confound the results. Much needs to be done - ideally, a large, multi-centre RCT is needed with strict control of co-interventions in order to determine the true effect of beta-2 agonists and ipratropium on the short and long term outcomes of patients with acute exacerbations of COPD. Studies should measure both the objective changes (i.e. FEV1, PEFR, PaO2) and the more subjective patient-oriented outcomes (quality of life, dyspnoea, symptom scores). This may not be possible because of ethical constraints in trying to perform research on therapies that have already become a part of standard and accepted patient care. </P>
<P>Tests of an additive or synergistic effect of these drugs need to be designed specifically to address this issue.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to acknowledge the following persons, without whom this project would not be possible: Mrs Karen Blackhall for obtaining all articles reviewed for this analysis; Dr. John White for his editing skills, and Mr. Steve Milan for his patience.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Backman-1985" NAME="Backman 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Reference List&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Backman R, Hellstrom P-E</AU>
<TI>Femoterol and Ipratropium bromide in respirator treatment of patients with chronic bronchitis</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1985</YR>
<VL>38</VL>
<NO>1</NO>
<PG>135-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karpel-1990" NAME="Karpel 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;1. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98(4):835-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karpel JP, Pesin J, Greenberg D, Gentry E</AU>
<TI>A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD</TI>
<SO>Chest</SO>
<YR>1990</YR>
<VL>98</VL>
<NO>4</NO>
<PG>835-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rebuck-1987" NAME="Rebuck 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;2. Rebuck AS, Chapman KR, Abboud R et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987; 82(1):59-64.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rebuck AS, Chapman KR, Abboud R et al</AU>
<TI>Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room</TI>
<SO>American Journal of Medicine</SO>
<YR>1987</YR>
<VL>82</VL>
<NO>1</NO>
<PG>59-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Cydulka-1995" NAME="Cydulka 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;1. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995; 25(4):470-3.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cydulka RK, Emerman CL</AU>
<TI>Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>4</NO>
<PG>470-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emerman-1997" NAME="Emerman 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Emerman CL, Cydulka RK. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Annals of Emergency Medicine 1997; 29(4):474-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Emerman CL, Cydulka RK</AU>
<TI>Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1997</YR>
<VL>29</VL>
<NO>4</NO>
<PG>474-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ikeda-1998" NAME="Ikeda 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Ikeda A, Nishimura K, Izumi T. Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease. Drugs &amp;amp; Aging 1998; 12(2):129-37.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda A, Nishimura K, Izumi T</AU>
<TI>Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Drugs &amp; Aging</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>2</NO>
<PG>129-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koutsogiannis-2000" NAME="Koutsogiannis 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koutsogiannis Z, Kelly AM</AU>
<TI>Does high dose ipratropium bromide added to salbutamol improve pulmonary function for patients with chronic obstructive airways disease in the emergency department?</TI>
<SO>Australian &amp; New Zealand Journal of Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>38-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lloberes-1988" NAME="Lloberes 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lloberes P, Ramis L, Montserrat JM et al</AU>
<TI>Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease</TI>
<SO>European Respiratory Journal</SO>
<YR>1988</YR>
<VL>1</VL>
<PG>536-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-1997" NAME="Lu 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Lu CC. Bronchodilator therapy for chronic obstructive pulmonary disease. [Review] [59 refs]. Respirology.  2(4):317-22, 1997 Dec .&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lu CC</AU>
<TI>Bronchodilator therapy for chronic obstructive pulmonary disease</TI>
<SO>Respirology</SO>
<YR>1997</YR>
<VL>2</VL>
<NO>4</NO>
<PG>317-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madison-1998" NAME="Madison 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet 1998; 352(9126):467-73.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Madison JM, Irwin RS</AU>
<TI>Chronic obstructive pulmonary disease</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9126</NO>
<PG>467-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matera-1996" NAME="Matera 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respiratory Medicine.  90(8):497-9, 1996 Sep .&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matera MG, Caputi M, Cazzola M</AU>
<TI>A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease</TI>
<SO>Respiratory Medicine</SO>
<YR>1996</YR>
<VL>90</VL>
<NO>8</NO>
<PG>497-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moayyedi-1995" NAME="Moayyedi 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;3. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50(8):834-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF</AU>
<TI>Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>8</NO>
<PG>834-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muir-1999" NAME="Muir 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Muir JF, Cuvelier A. Nebulization with bronchodilating agents in bronchial obstruction. Revue Des Maladies Respiratoires 1999; 16(SUPPL. 3):3S41-3.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muir JF, Cuvelier A</AU>
<TI>Nebulization with bronchodilating agents in bronchial obstruction</TI>
<SO>Revue Des Maladies Respiratoires</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>SUPPL. 3</NO>
<PG>3S41-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musil-1996" NAME="Musil 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Musil J, Vondra V. Combined inhalation therapy with bronchodilator solutions in airways obstruction (a contribution or risk?). Studia Pneumologica Et Phtiseologica, Vol 56(6) (Pp 243-247), 1996 .&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Musil J, Vondra V</AU>
<TI>Combined inhalation therapy with bronchodilator solutions in airways obstruction (a contribution or risk?)</TI>
<SO>Studia Pneumologica Et Phtiseologica</SO>
<YR>1996</YR>
<VL>Vol 56(6)</VL>
<PG>243-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musil-1997" NAME="Musil 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Musil J, Vondra V. Do we have to fear inhalation of salbutamol solution in severe acute bronchial obstruction? Prakticky Lekar, Vol 77(1) (Pp 29-31), 1997 .&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Musil J, Vondra V</AU>
<TI>Do we have to fear inhalation of salbutamol solution in severe acute bronchial obstruction?</TI>
<SO>Prakticky Lekar</SO>
<YR>1997</YR>
<VL>77(1)</VL>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musil-1998" NAME="Musil 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Musil J, Hirsch V, Vondra V, Reisova M. What is the adequate dose in combined inhalation treatment of patients with exacerbations of chronic obstructive pulmonary disease? Vnitrni Lekarstvi 1998; 44(7):415-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Musil J, Hirsch V, Vondra V, Reisova M</AU>
<TI>What is the adequate dose in combined inhalation treatment of patients with exacerbations of chronic obstructive pulmonary disease?</TI>
<SO>Vnitrni Lekarstvi</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>7</NO>
<PG>415-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naberan-1998" NAME="Naberan 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Naberan K. [Bronchodilator treatment of COPD]. [Review] [34 refs] [Spanish]. Atencion Primaria.  21(2):109-13, 1998 Feb 15 .&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Naberan K</AU>
<TI>[Bronchodilator treatment of COPD. Article in Spanish]</TI>
<SO>Atencion Primaria</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>2</NO>
<PG>109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patrick-1990" NAME="Patrick 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;4. Patrick DM, Dales RE, Stark RM, Laliberte G, Dickinson G. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990; 98(2):295-7.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Patrick DM, Dales RE, Stark RM, Laliberte G, Dickinson G</AU>
<TI>Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy</TI>
<SO>Chest</SO>
<YR>1990</YR>
<VL>98</VL>
<NO>2</NO>
<PG>295-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perri-1985" NAME="Perri 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;5. Perri G, Giovannini M, Spada E. Salbutamol plus beclomethasone dipropionate (Ventolin Flogo) vs. fenoterol (Dosberotec) in chronic obstructive lung disease therapeutic strategy: a 4-week clinical trial. Int J Clin Pharmacol Ther Toxicol 1985; 23(5):274-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perri G, Giovannini M, Spada E</AU>
<TI>Salbutamol plus beclomethasone dipropionate (Ventolin Flogo) vs. fenoterol (Dosberotec) in chronic obstructive lung disease therapeutic strategy: a 4-week clinical trial</TI>
<SO>International Journal of Clinical Pharmacology, Therapy, &amp; Toxicology</SO>
<YR>1985</YR>
<VL>23</VL>
<NO>5</NO>
<PG>274-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phanareth-1997" NAME="Phanareth 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Phanareth K, Hansen EF, Laursen LC. Treatment of severe acute exacerbation of asthma and chronic obstructive pulmonary disease. Ugeskrift for Laeger 1997; 159(47):6985-91.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Phanareth K, Hansen EF, Laursen LC</AU>
<TI>Treatment of severe acute exacerbation of asthma and chronic obstructive pulmonary disease</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1997</YR>
<VL>159</VL>
<NO>47</NO>
<PG>6985-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1998" NAME="Rees 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Rees PJ. Bronchodilators in the therapy of chronic obstructive pulmonary disease. EUR RESPIR MONOGR, Vol 3(7) (Pp 135-149), 1998 .&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rees PJ</AU>
<TI>Bronchodilators in the therapy of chronic obstructive pulmonary disease</TI>
<SO>European Respiratory Monograph</SO>
<YR>1998</YR>
<VL>3(7)</VL>
<PG>135-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shrestha-1991" NAME="Shrestha 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;6. Shrestha M, O'Brien T, Haddox R, Gourlay HS, Reed G. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy. Ann Emerg Med 1991; 20(11):1206-9.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shrestha M, O'Brien T, Haddox R, Gourlay HS, Reed G</AU>
<TI>Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1206-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wortmann_x002d_Schmid-1999" NAME="Wortmann-Schmid 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Wortmann-Schmid B. Exacerbation of chronic obstructive bronchitis. Therapiewoche Schweiz 1999; 15(2):74-5.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wortmann-Schmid B</AU>
<TI>Exacerbation of chronic obstructive bronchitis</TI>
<SO>Therapiewoche Schweiz</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>2</NO>
<PG>74-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zehner-1995" NAME="Zehner 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;3. Zehner WJ Jr, Scott JM, Iannolo PM, Ungaro A, Terndrup TE. Terbutaline vs albuterol for out-of-hospital respiratory distress: randomized, double-blind trial. Acad Emerg Med 1995; 2(8):686-91.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zehner WJ Jr, Scott JM, Iannolo PM, Ungaro A, Terndrup TE</AU>
<TI>Terbutaline vs albuterol for out-of-hospital respiratory distress: randomized, double-blind trial</TI>
<SO>Academic Emergency Medicine</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>8</NO>
<PG>686-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-American-1995" MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="American 1995" NOTES="&lt;p&gt;American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77-121.&lt;/p&gt;" NOTES_MODIFIED="2008-07-30 15:54:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>American Thoracic Society</AU>
<TI>Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>5 Pt 2</NO>
<PG>S77-121</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96048961"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Anthonisen-1987" MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Anthonisen 1987" NOTES="&lt;p&gt;Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.&lt;/p&gt;" NOTES_MODIFIED="2008-07-30 15:54:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA</AU>
<TI>Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<PG>196-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1-12.&lt;/p&gt;" NOTES_MODIFIED="2008-07-30 15:54:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96308458"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1992" MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Murphy 1992" NOTES="&lt;p&gt;Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;146:1067-83.&lt;/p&gt;" NOTES_MODIFIED="2008-07-30 15:54:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Murphy TF, Sethi S</AU>
<TI>Bacterial infection in chronic obstructive pulmonary disease</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>146</VL>
<NO>4</NO>
<PG>1067-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93036759"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Siafakas-1995" MODIFIED="2008-07-30 15:54:02 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Siafakas 1995" NOTES="&lt;p&gt;Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8:1398-420.&lt;/p&gt;" NOTES_MODIFIED="2008-07-30 15:54:02 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al</AU>
<TI>Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>8</NO>
<PG>1398-420</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="96087552"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-30 15:56:14 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Backman-1985">
<CHAR_METHODS>
<P>Design: SPPG<BR/>Location: Finland<BR/>Assessment period: 7 days</P>
<P>External validity: 2/5<BR/>COPD dx-<BR/>COPD bl-<BR/>AECB dx-<BR/>AECB sev+<BR/>Tx duration+</P>
<P>Internal validity: 3/5<BR/>r, db, dd<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 40<BR/>Trial included both pts with acute asthma (n = 150) and pts with acute exacerbation of COPD (n = 52). Most results were reported separately for the two types of patients.<BR/>Setting: Hospitalized pts FEV1</P>
<P>Inclusion (COPD): Chronic bronchitis, according to criteria of the British Medical Council [no ref given]</P>
<P>Inclusion (AcEx): Acute exacerbation of chronic bronchitis (no diagnostic criteria given)</P>
<P>Exclusion: N/S</P>
<P>Smoking history: N/S</P>
<P>Baseline stable FEV1: N/S</P>
<P>FEV1 before treatment on day 1: Ipratropium, 0.73 ± 0.35 (SD) L; fenoterol, 0.93 ± 0.56 L (n.s.; p-value not reported)</P>
<P>Age: Range: 48-77<BR/>Sex: 36 M, 4 F<BR/>Race: N/S</P>
<P>Dropouts: 1/40 pts (2.5%), treatment group N/S</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Nebulized ipratropium 0.2 mg, 3x/day</P>
<P>Control: Nebulized fenoterol 0.5 mg, 3x/day</P>
<P>Co-interventions: Pts with signs of an acute infection (fever, pneumonic infiltration, and positive sputum bacteriology) were treated with antibiotics before the start of the trial; pts taking beta2-receptor stimulants (n = 16) stopped them at least 8 hrs before starting the trial; all pts received daily physical treatment; otherwise, pts continued their usual regimens, which included oral theophyllamine (n = 7), combination treatment with ephedrine and hydroxyzine (n = 4), prednisolone (n = 2), and no continuous treatment (n = 7)</P>
<P/>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1: Measured on the 1st and 7th day immediately before and 5, 10, 15, 30, 60, 120, and 240 min after the morning study drug administration. Investigators compared mean FEV1 scores for identical timepoints on days 1 and 7.</P>
<P>Blood gases: Arterial PaO2 and PaCO2 measured on 1st and 7th day. Investigators analyzed change from day 1 to 7.</P>
<P>There were no significant differences between the two treatment groups for any of the outcomes measured (no between-group p-values reported).</P>
<P>Dropouts: 1/40 pts (2.5%), treatment group N/S<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>RESULTS: FEV1 improvements were small with both interventions. In the ipratropium group (n = 17), mean scores at 15 min (p &lt; 0.02) and 30 min (p &lt; 0.05) post-treatment were significantly higher on the 7th day than on the 1st; no significant differences were noted between the 1st and 7th day at 0, 5, 10, 60, 120, or 240 min. In the fenoterol group (n = 20), mean scores at 60 min post-treatment were significantly higher on the 7th day than on the 1st (p &lt; 0.05); otherwise, no significant differences were observed between the 1st and 7th day.</P>
<P>Mean pre-treatment FEV1 scores on days 1 and 7 were:</P>
<P>(a) Ipratropium (n = 17): Day 1, 0.73 ± 0.35 (SD) L; Day 7, 0.82 ± 0.34 L<BR/>(b) Fenoterol (n = 20): Day 1, 0.93 ± 0.56 L; Day 7, 1.02 ± 0.66 L</P>
<P>Blood gases/oximetry: Investigators stated that there were no significant changes in PaO2 or PaCO2 from day 1 to day 7 in either group, but did not report any data.</P>
<P>Adverse events: 1/19 pts (5%) taking ipratropium and 1/20 (5%) taking fenoterol complained of a "strange feeling"<BR/>Two pts in the ipratropium group who did not withdraw prematurely were unable to perform spirometry and so were not included in the FEV1 analysis</P>
<P/>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Karpel-1990">
<CHAR_METHODS>
<P>Design: CrOv</P>
<P>Dates: N/S</P>
<P>Location: US</P>
<P>Assessment period: 90 min for each phase of crossover</P>
<P>External validity: 3/5<BR/>COPD dx+<BR/>COPD bl-<BR/>AECB dx+<BR/>AECB sev+<BR/>Tx duration-</P>
<P>Internal validity: 5/5<BR/>r+, db+, dd<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 32</P>
<P>Setting: ED and pulmonary clinic</P>
<P>Inclusion (COPD): Chronic bronchitis or emphysema as defined by the ATS Committee on Diagnostic Standards for Nontuberculous Respiratory Disease (1962)</P>
<P>Inclusion (AcEx): Increasing dyspnea and/or change in sputum production newly occurring in previous 24 hrs; FEV1 &lt; 60% of predicted</P>
<P>Exclusion: Asthma; baseline pulmonary function tests which failed to show persistent airway obstruction; any acute concomitant medical problem; respiratory acidosis with pH &lt; 7.3; need for continuous oxygen therapy; need for medications other than those included in study protocol; use of inhaled b-agonist or ipratropium in previous 6 hrs</P>
<P>Smoking history: N/S</P>
<P>Baseline stable FEV1: N/S</P>
<P>FEV1 at admission: Ipratropium first: 0.62 ± 0.08 (SEM) L; metaproterenol first: 0.69 ± 0.06 L</P>
<P>Age: 61.6<BR/>Sex: N/S<BR/>Race: N/S<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Ipratropium, single dose of 3 puffs (54 mg) administered by MDI</P>
<P>Control: Metaproterenol, single dose of 3 puffs (1.95 mg) administered by MDI</P>
<P>Co-interventions: None</P>
<P>
<BR/>Crossover design: Pts treated with one of the two study meds initially (phase 1), then crossed over to treatment with the other after 90 min (phase 2); no washout; no information on possible carry-over effect<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1: Measured at entry and at 30, 60, and 90 min after administration of study med in both phases of crossover; investigators analyzed change in mean FEV1 from 0 to 90 min in phase 1</P>
<P>Blood gases: Recorded only for the first 20 pts randomized into the study; measured at entry and at 30, 60, and 90 min after administration of study med in phase 1 only; investigators analyzed mean changes in PaO2, PaCO2, and pH from 0-30 min and 0-90 min</P>
<P>Percentage of pts admitted to hospital</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>RESULTS: In phase 1 of the trial, mean FEV1 (± SEM) improved significantly in both treatment groups from 0-90 min. For ipratropium (n = 17), scores improved 25%, from 0.62 ± 0.08 to 0.88 ± 0.11 (p&lt; 0.01). For metaproterenol (n = 15), the improvement was 18%, from 0.69 ± 0.06 to 0.92 ± 0.09 (p&lt; 0.01). There was no significant difference between the two groups for this outcome (p &gt; 0.05).</P>
<P>For phase 2 of the trial, investigators reported only that there was no further improvement in FEV1 in either group.</P>
<P>Blood gases: At 30 min, there was a significant (p &lt; 0.05) rise in PaO2 with ipratropium (n = 10) (5.8 ± 3.0 [SEM]), and a significant (p &lt; 0.05) decline in PaO2 with metaproterenol (n = 10) (-6.2 ± 1.2). At 90 min, these changes were no longer significant.</P>
<P>There were no other significant changes in PO2, PCO2, or pH during phase 1.</P>
<P>Percentage of pts admitted to hospital: 3/17 pts (18%) from the ipratropium-first group, 2/15 pts (13%) from the metaproterenol-first group.</P>
<P>
<BR/>Adverse events: Recorded for phase 1 only. Ipratropium: Nervousness (2 pts), tremors (2), dry mouth (1), palpitations (1), headache (1). Metaproterenol: Palpitations (3 pts), nervousness (3), tremors (2), dry mouth (1), headache (1).</P>
<P>Dropouts: 0<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rebuck-1987">
<CHAR_METHODS>
<P>Design: SPPG</P>
<P>Dates: N/S</P>
<P>Location: Canada</P>
<P>Assessment period: 90 min</P>
<P>External validity: 2/5<BR/>COPD dx+<BR/>COPD bl-<BR/>AECB dx-<BR/>AECB sev+<BR/>Tx duration-</P>
<P>Internal validity: 5/5<BR/>r+, db+, dd<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N = 52 with acute exacerbation of COPD (see Notes)</P>
<P>Setting: 4 EDs</P>
<P>Inclusion (COPD): ATS criteria (1962)</P>
<P>Inclusion (AcEx): Age &gt; 18 yrs; FEV1 &lt; 70% of predicted</P>
<P>Exclusion: Complicating medical illnesses (e.g., pneumonia, pulmonary edema, acute myocardial infarction, frequent ventricular ectopic beats); pregnancy or breastfeeding; use of nebulized bronchodilator in previous 6 hrs; need for medications other than those specified in study protocol</P>
<P>Smoking history: N/S</P>
<P>Baseline stable FEV1: N/S</P>
<P>FEV1 at admission: 0.67 ± 0.29 (SD) L (28% of predicted) (COPD pts only)</P>
<P>Age: 66.2 (COPD pts only)<BR/>Sex: 28 M, 23 F<BR/>Race: N/S<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: Nebulized ipratropium 0.5 mg + fenoterol 1.25 mg, single dose</P>
<P>Control 1: Nebulized ipratropium 0.5 mg, single dose</P>
<P>Control 2: Nebulized fenoterol 1.25 mg, single dose</P>
<P>Co-interventions: Aminophylline IV or corticosteroids IV could be used at discretion of attending physician; all other drugs proscribed<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1: Mean change from pre-treatment to 45 and 90 min</P>
<P/>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>RESULTS<BR/>FEV1: Each of the three treatment regimens produced a significant improvement in FEV1 from 0 to 90 min (p &lt; 0.05). There was no significant difference among the three treatments for this outcome (p &lt; 0.2). Mean improvement scores (± SEM) were reported in graphic form only. Pre-treatment and 90-min mean FEV1 scores (± SD) for the three groups were:</P>
<P>Fenoterol: Pre-: 0.69 ± 0.30; 90-min: 0.88 ± 0.44</P>
<P>Ipratropium: Pre-: 0.69 ± 0.26; 90-min: 0.89 ± 0.41</P>
<P>Ip + Fen: Pre-: 0.63 ± 0.31; 90-min: 0.80 ± 0.40</P>
<P>Adverse events: Pts were questioned about specific AEs. Results were not reported separately for pts with asthma and COPD. The most commonly reported AEs were dry mouth (10.6% of pts taking combination treatment, 19.1% taking fenoterol alone, 7.4% taking ipratropium alone); tremor (16.7% of pts taking combination treatment, 13.2% taking fenoterol alone, 2.9% taking ipratropium alone); and bad taste (8.4% overall). Eye irritation, sweating, and dizziness were each reported by &lt; 3% of pts overall.</P>
<P>Dropouts: 1/52 pts (2%), from ipratropium group.<BR/>No significant difference in the proportion of COPD pts receiving aminophylline IV and cortico-steroids IV in the three treatment groups.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-30 15:56:14 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Cydulka-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study is not designed to measure the effects of a beta-2 agonist.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Emerman-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study is not designed to measure the effects of a beta-2 agonist.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ikeda-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Nonsystematic review of the literature</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koutsogiannis-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The study was not included because although all patients were having COPD exacerbations, they were given both salbutamol and ipratropium at time=0 in the study. They then received either salbutamol, ipratropium or both at 15 minutes and 30 minutes after that. The initial medications given make it impossible to determine the effect on FEV-1 of either drug alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-30 15:56:14 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Lloberes-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-30 15:56:14 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Patient population considered immediately recovered from an exacerbation of COPD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lu-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>A non-systematic review of the literature on the use of bronchodilators in COPD treatment (stable and exacerbations)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Madison-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>A non-systematic review of the literature on COPD treatment (stable and exacerbations)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matera-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Population studied were stable COPD patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moayyedi-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study is designed to measure the effects of ipratropium not a beta-2 agonist.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muir-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>An expert review of COPD treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Musil-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study is not designed to measure the effects of a beta-2 agonist.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Musil-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>20 patients with COPD and asthma exacerbations treated - data not subdivided by underlying diagnosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Musil-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dosing study of an ipratropium/phenoterol combination product</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naberan-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Systematic review ( no meta-analysis) with expert opinion treatment recommendations</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patrick-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study is designed to measure the effects of ipratropium not a beta-2 agonist.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perri-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>A randomized study to evaluate the effects of an inhaled steroid in combination with a beta-2 agonist.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Phanareth-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Telephone survey to determine actual treatment regimens prescribed to patients with COPD and asthma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rees-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Nonsystematic review/ expert opinion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shrestha-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study is designed to measure the effects of ipratropium not a beta-2 agonist.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wortmann_x002d_Schmid-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>A review of the ATS guidelines for treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zehner-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>83 patients with either asthma or COPD exacerbations - unable to reliably determine the specific underlying disease in each patient so the results are pooled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-30 15:56:11 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-30 15:56:11 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-30 15:55:39 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Backman-1985">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-30 15:56:00 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Karpel-1990">
<DESCRIPTION>
<P>Third party randomisation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-30 15:56:11 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Rebuck-1987">
<DESCRIPTION>
<P>Third party randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-30 15:56:30 +0100" MODIFIED_BY="Toby J Lasserson">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-30 15:56:30 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>Beta2-Agonist vs. Ipratropium</NAME>
<CONT_OUTCOME CHI2="0.21518211511394703" CI_END="0.22954560712218436" CI_START="-0.2189164876878012" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.005314559717191579" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2008-07-30 15:56:30 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.8979947514845433" P_Q="1.0" P_Z="0.9629486937299742" Q="0.0" RANDOM="NO" SCALE="1.3409500025233398" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="0.046453627898234304">
<NAME>Change in FEV1 (L) over 90 minutes</NAME>
<GROUP_LABEL_1>Beta2-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Ipratropium</GROUP_LABEL_2>
<GRAPH_LABEL_1>ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>beta2-agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6115994364684931" CI_START="-0.39159943646849316" EFFECT_SIZE="0.11000000000000001" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="0.15" ORDER="572" SD_1="0.52" SD_2="0.94" SE="0.2559227824720482" STUDY_ID="STD-Backman-1985" TOTAL_1="20" TOTAL_2="17" WEIGHT="19.98376947972287"/>
<CONT_DATA CI_END="0.31064522976973186" CI_START="-0.3706452297697319" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.26" ORDER="573" SD_1="0.42" SD_2="0.56" SE="0.17380178026570792" STUDY_ID="STD-Karpel-1990" TOTAL_1="15" TOTAL_2="17" WEIGHT="43.32981829237932"/>
<CONT_DATA CI_END="0.3602057200067766" CI_START="-0.3802057200067766" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.2" ORDER="574" SD_1="0.62" SD_2="0.48" SE="0.188883940177938" STUDY_ID="STD-Rebuck-1987" TOTAL_1="20" TOTAL_2="14" WEIGHT="36.68641222789782"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2664561609649487" CI_END="54.28151454366629" CI_START="-43.92350258229715" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.179005980684575" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.605719025277908" P_Q="1.0" P_Z="0.8362254414318371" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="0.20672396370216975">
<NAME>Change in PEFR (l/min) over 90 minutes</NAME>
<GROUP_LABEL_1>Beta2-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Ipratropium</GROUP_LABEL_2>
<GRAPH_LABEL_1>ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>beta2-agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="107.82883465436188" CI_START="-61.22883465436189" EFFECT_SIZE="23.299999999999997" ESTIMABLE="YES" MEAN_1="39.4" MEAN_2="16.1" ORDER="575" SD_1="99.79" SD_2="152.17" SE="43.12774893881446" STUDY_ID="STD-Backman-1985" TOTAL_1="20" TOTAL_2="17" WEIGHT="33.74408036813374"/>
<CONT_DATA CI_END="56.27416745860266" CI_START="-64.37416745860266" EFFECT_SIZE="-4.050000000000001" ESTIMABLE="YES" MEAN_1="30.09" MEAN_2="34.14" ORDER="576" SD_1="84.51" SD_2="90.9" SE="30.778202015155376" STUDY_ID="STD-Rebuck-1987" TOTAL_1="20" TOTAL_2="14" WEIGHT="66.25591963186626"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5966863587442726" CI_START="-0.4566863587442726" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.07" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7944844380767246" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="0.2604918024550902">
<NAME>Change in FEV1 (L) over 7 days</NAME>
<GROUP_LABEL_1>Beta2-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Ipratropium</GROUP_LABEL_2>
<GRAPH_LABEL_1>ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>beta2-agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5966863587442726" CI_START="-0.4566863587442726" EFFECT_SIZE="0.07" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="0.19" ORDER="577" SD_1="0.6" SD_2="0.96" SE="0.2687224678099737" STUDY_ID="STD-Backman-1985" TOTAL_1="20" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="51.74796733991057" CI_START="-104.94796733991056" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-26.599999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5057758810976101" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="0.6654294139193037">
<NAME>Change in PEFR (l/min) over 7 days</NAME>
<GROUP_LABEL_1>Beta2-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Ipratropium</GROUP_LABEL_2>
<GRAPH_LABEL_1>ipratropium</GRAPH_LABEL_1>
<GRAPH_LABEL_2>beta2-agonist</GRAPH_LABEL_2>
<CONT_DATA CI_END="51.74796733991057" CI_START="-104.94796733991056" EFFECT_SIZE="-26.599999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="29.4" ORDER="578" SD_1="142.6" SD_2="99.4" SE="39.97418725951565" STUDY_ID="STD-Backman-1985" TOTAL_1="20" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.0140831224415387E-31" CI_END="-5.658373048353696" CI_START="-18.341626951646308" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.000000000000002" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="2.0827731566576969E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="3.7087592811454964">
<NAME>Change in pO2 (mm Hg) within 30 minutes</NAME>
<GROUP_LABEL_1>Beta2-agonist</GROUP_LABEL_1>
<GROUP_LABEL_2>Ipratropium</GROUP_LABEL_2>
<GRAPH_LABEL_1>beta2-agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>ipratropium</GRAPH_LABEL_2>
<CONT_DATA CI_END="-5.6583730483536945" CI_START="-18.341626951646305" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="-6.2" MEAN_2="5.8" ORDER="579" SD_1="3.8" SD_2="9.5" SE="3.2355834095260163" STUDY_ID="STD-Karpel-1990" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.287032671143837" CI_START="-9.967032671143837" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8399999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6572266362344663" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.4437454452913042">
<NAME>Change in pCO2 (mm Hg) within 30 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.287032671143837" CI_START="-9.967032671143837" EFFECT_SIZE="-1.8399999999999999" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="1.9" ORDER="580" SD_1="12.08" SD_2="5.1" SE="4.146521433683901" STUDY_ID="STD-Karpel-1990" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-07-30 15:57:01 +0100" MODIFIED_BY="Toby J Lasserson">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-07-30 15:57:01 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Beta2-Agonist vs. Ipratropium, outcome: 1.1 Change in FEV1 (L) over 90 minutes.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtgAAACgCAMAAAAB4+uyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>